Antenatal corticosteroids for fetal lung maturation have become mainstay treatment in women thought to be at high-risk of premature birth. To ensure treatment efficacy before delivery, the current practice is to administer steroids early to a woman considered at risk; however, neonatal benefit is lost after the seven-day treatment-to-delivery window. Over half of women who deliver before 34 weeks’ gestation do not receive antenatal corticosteroids within this timeframe, but many still deliver prematurely; however, clinicians are reluctant to administer repeated courses of steroids due to concerns, among others, of impaired fetal growth. However, evidence is mounting regarding the optimal timing for steroids, including substantive benefits close to delivery, and the benefits of repeated courses if delivery has not occurred. Better targeted treatment is required to allow for maximum benefit; reducing unnecessary treatment in low-risk women, while targeting therapy in the high-risk cohort and offering repeat courses if the seven-day window is exceeded. Novel tools to aid prediction may help implement this strategy.
AdamsTMKinzlerWLChavezMR. The timing of administration of antenatal corticosteroids in women with indicated preterm birth. Am J Obstet Gynecol2014; 212: 645.e1–4–645.e1–4.
2.
March of Dimes, PMNCH, Save the Children, WHO. Born too soon: the global action report on preterm birth. CP Howson, MV Kinney and JE Lawn (eds.). Geneva: World Health Organization, 2012.
3.
PeacemanAMAndrewsWWThorpJM. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol1997; 177: 13–18.
4.
LigginsGC. Premature delivery of foetal lambs infused with corticosteroids. J Endocrinol1969; 45: 515–523.
5.
LigginsGCHowieRN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics1972; 50: 515–525.
CrowleyPChalmerIKeirseMJ. The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. Br J Obstet Gynaecol1990; 97: 11–25.
8.
The effect of antenatal steroids for fetal maturation on perinatal outcomes. NIH Consensus Statement 1994; 12: 1–24.
9.
Committee on Obstetric Practice. ACOG committee opinion: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol2002; 99: 871–871.
RobertsDDalzielSR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Syst Rev2006; 3: CD004454–CD004454.
12.
BarkerDJP. Mothers, babies and health in later life, 2nd ed. London: Churchill Livingstone, 1998.
13.
DodicMWintourEMWhitworthJA. Effect of steroid hormones on blood pressure. Clin Exp Pharmol Physiol1999; 26: 550–552.
14.
CrowtherCAMcKinlayCJDMiddletonP. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Syst Rev2011; 6: CD003935–CD003935.
15.
CrowtherCAHaslamRRHillerJE. Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. Lancet2006; 367: 1913–1919.
16.
McKinlayCJCutfieldWSBattinMR. Cardiovascular risk factors in children after repeat doses of antenatal glucocorticoids: an RCT. Pediatrics2015; 135: e405–e415.
17.
MurphyKEHannahMEWillanAR. Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. Lancet2008; 372: 2143–2151.
18.
WapnerRJYoramSThomEA. Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy. Am J Obstet Gynecol2006; 195: 633–642.
19.
Royal College of Obstetricians and Gynaecologists. Antenatal corticosteroids to reduce neonatal morbidity and mortality [Green-top Guideline No. 7], London (UK): RCOG, 2010.
20.
SanyaRAl NaggarEGasimM. Use or overuse of antenatal corticosteroids for suspected preterm birth. J Matern Fetal Neonatal Med2014; 27: 1454–1456.
21.
BoltLAChandiramaniMde GreeffA. The value of combined cervical length measurement and fetal fibronectin testing to predict spontaneous preterm birth in asymptomatic high risk women. J Matern Fetal Neonatal Med2011; 24: 928–932.
22.
IamsJDCasalDMcGregorJA. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol1995; 173: 141–145.
23.
AbbottDSRadfordSKSeedPT. Evaluation of quantitative fetal fibronectin test for spontaneous birth in symptomatic women. Am J Obstet Gynecol2013; 208: 122.e1–6–122.e1–6.
24.
CooperSLangeIWoodS. Diagnostic accuracy of rapid phIGFBP-I assay for predicting preterm labor in symptomatic patients. J Perinatol2011; 32: 460–465.
25.
NikolovaTBayevONikolovaN. Evaluation of a novel placental alpha microglobulin-1 (PAMG-1) test to predict spontaneous preterm delivery. J Perinat Med2014; 42: 473–477.
26.
FuchsIHenrichWOsthuesK. Sonographic cervical length in singleton pregnancies with intact membranes presenting with threatened preterm labor. Ultrasound Obstet Gynecol2004; 24: 554–557.
27.
SotiriadisAPapatheodorouSKavvadiasA. Transvaginal cervical length measurement for prediction of preterm birth in women with threatened preterm labor: a meta-analysis. Ultrasound Obstet Gynecol2010; 35: 54–64.
28.
DeFrancoEALewisDFOdiboAO. Improving the screening accuracy for preterm labor: is the combination of fetal fibronectin and cervical length in symptomatic patients a useful predictor of preterm birth? A systematic review. Am J Obstet Gynecol2013; 208: 233.e1–6.
29.
ChappellLCDuckworthSSeedPT. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation2013; 128: 2121–2131.
30.
SotiriadisAMakrydimasGPapatheodorouS. Corticosteroids for preventing neontatal respiratory morbidity after elective caesarean section at term. Cochrane Database Syst Rev2009; 4: CD006614–CD006614.
31.
Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Timing of elective caesarean section at term. College Statement C-Obs 23, 2014.
